Supplementary Figure S4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Supplementary Figure</p

Supplementary Table 4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Plasma pharmacokinetic comparisons of C86, C91, and C99 in mice for parameters outlined in the table.</p

Supplementary Table 2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Table comparing various key pharmacokinetic parameters (Assay, left column) between C-91 and C-86.</p

Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Supplementary Figure</p

Supplementary Data Legends from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Legends for supplementary figures and tables.</p

Supplementary Figure S3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Supplementary Figure</p

Supplementary Table 3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Safetyscreen assay for C86 performed at eurofins.</p

Supplementary Table 5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Tissue pharmacokinetics and bio-distribution of C86 at two different does through the intraperitoneal route.</p

Supplementary Figure S5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Supplementary Figure</p

Supplementary Figure S2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Supplementary Figure 2</p